Capital Bank & Trust’s Moderna MRNA Stock Holding History

Capital Bank & Trust’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-11	Closed	–	–	519
2020 Q1	$0	Buy	+11	New	+$253	﹤0.01%	757

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital Bank & Trust's MRNA Position: Q2 2020 in Review

Capital Bank & Trust sold out of Moderna (MRNA) in Q2 2020, closing a stake of 11 shares.

Capital Bank & Trust first reported a position in MRNA in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 490 funds tracked by Wall St. Rank hold MRNA as of Q2 2020.

Capital Bank & Trust reported no remaining Moderna position as of Q2 2020 after selling out during the quarter.
Capital Bank & Trust sold 11 Moderna shares in Q2 2020.
Capital Bank & Trust first reported a position in Moderna in Q1 2020 and held it in 1 quarter.
Capital Bank & Trust's Moderna position peaked at $0 in Q1 2020.
490 funds tracked by Wall St. Rank held Moderna as of Q2 2020.

Based on Capital Bank & Trust's 13F filing for Q2 2020, filed 14 Aug 2020.